Concepedia

Publication | Open Access

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

DOIFull Paper Access

564

Citations

13

References

2019

Year

Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik, Sumit Shah, Sreenivasa R Chandana, Drew Rasco, A. Dimitrios Colevas, Timothy J. O’Rourke, Sujata Narayanan, Kyriakos P. Papadopoulos,
Journal of Clinical Oncology

Abstract

5F9 is well tolerated using a priming dose at 1 mg/kg on day 1 followed by maintenance doses of up to 45 mg/kg weekly.

References

YearCitations

Page 1